Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Exelixis, Inc.
  6. News
  7. Summary
    EXEL   US30161Q1040

EXELIXIS, INC.

(EXEL)
  Report
Real-time Estimate Quote. Real-time Estimate Cboe BZX - 12/01 04:51:15 pm
16.645 USD   -0.86%
11/22Exelixis Announces Detailed Results from Phase 3 COSMIC-312 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver Cancer at ESMO Asia Virtual Oncology Week 2021
AQ
11/20Exelixis Announces Detailed Results from Phase 3 COSMIC-312 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver Cancer at ESMO Asia Virtual Oncology Week 2021
BU
11/20Exelixis Announces Detailed Results from Phase 3 Cosmic-312 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver Cancer At Esmo Asia Virtual Oncology Week 2021
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
 SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Most relevant news about EXELIXIS, INC.
11/22Exelixis Announces Detailed Results from Phase 3 COSMIC-312 Pivotal Trial of Cabozantin..
AQ
11/20Exelixis Announces Detailed Results from Phase 3 COSMIC-312 Pivotal Trial of Cabozantin..
BU
11/20Exelixis Announces Detailed Results from Phase 3 Cosmic-312 Pivotal Trial of Cabozantin..
CI
11/09Exelixis Says Enrollment Complete For Phase 3 Trial For Cabozantinib in Combination Wit..
MT
11/09Exelixis Announces Enrollment Completion in Phase 3 CONTACT-01 Pivotal Trial of Cabozan..
BU
11/09Exelixis Announces Enrollment Completion in Phase 3 CONTACT-01 Pivotal Trial of Cabozan..
CI
11/03Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in November ..
BU
11/03Jefferies Starts Exelixis' at Buy with $28 Price Target
MT
11/03HC Wainwright Adjusts Price Target on Exelixis to $52 From $65, Keeps Buy Rating
MT
11/03Exelixis Posts Higher Q3 Results, Guides Full-Year Revenue Below Street Views; Shares S..
MT
11/02EXELIXIS : Q3 Earnings Snapshot
AQ
11/02Exelixis Q3 Earnings Slides With Appendix
PU
11/02EXELIXIS ANNOUNCES THIRD QUARTER 2021 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE -..
PU
11/02Earnings Flash (EXEL) EXELIXIS Posts Q3 Revenue $328.4M, vs. Street Est of $355.1M
MT
11/02Earnings Flash (EXEL) EXELIXIS Reports Q3 EPS $0.20, vs. Street Est of $0.26
MT
More most relevant news
All news about EXELIXIS, INC.
11/22Exelixis Announces Detailed Results from Phase 3 COSMIC-312 Pivotal Trial of Cabozantin..
AQ
11/20Exelixis Announces Detailed Results from Phase 3 COSMIC-312 Pivotal Trial of Cabozantin..
BU
11/20Exelixis Announces Detailed Results from Phase 3 Cosmic-312 Pivotal Trial of Cabozantin..
CI
11/09Exelixis Says Enrollment Complete For Phase 3 Trial For Cabozantinib in Combination Wit..
MT
11/09Exelixis Announces Enrollment Completion in Phase 3 CONTACT-01 Pivotal Trial of Cabozan..
BU
11/09Exelixis Announces Enrollment Completion in Phase 3 CONTACT-01 Pivotal Trial of Cabozan..
CI
11/03Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in November ..
BU
11/03Jefferies Starts Exelixis' at Buy with $28 Price Target
MT
11/03Fresh data highlights strength of US economy ahead of Fed meeting
11/03HC Wainwright Adjusts Price Target on Exelixis to $52 From $65, Keeps Buy Rating
MT
More news
News in other languages on EXELIXIS, INC.
11/09Exelixis annonce que le recrutement est terminé pour l'essai de phase 3 sur le cabozant..
11/03Exelixis affiche des résultats plus élevés au troisième trimestre, mais son chiffre d'a..
11/02Earnings Flash (EXEL) EXELIXIS affiche un chiffre d'affaires de 328,4 millions de dolla..
11/02Exelixis, Inc. fournit des prévisions de résultats pour l'ensemble de l'année 2021
11/02HISTORIQUE DES RÉACTIONS AUX RÉSULTA : Exelixis Inc, indicateur de suivi de 30,0%, sensibl..
10/14Exelixis et Storm Therapeutics signent un accord de collaboration et de licence pour dé..
09/20Exelixis annonce les résultats finaux de l'essai de phase 3 du traitement du cancer de ..
09/17Exelixis obtient l'approbation de la FDA pour Cabometyx dans le traitement du cancer de..
09/16Exelixis déclare que de nouvelles données exploratoires issues d'un essai de phase avan..
09/07Décès du médecin-chef d'Exelixis
More news
Analyst Recommendations on EXELIXIS, INC.
11/03Jefferies Starts Exelixis' at Buy with $28 Price Target
MT
11/03HC Wainwright Adjusts Price Target on Exelixis to $52 From $65, Keeps Buy Rating
MT
11/02Oppenheimer Adjusts Exelixis' Price Target to $29 From $30, Maintains Outperform Rating
MT
10/07EXELIXIS : Jefferies Starts Exelixis at Buy with $28 Price Target
MT
09/20EXELIXIS : Truist Securities Adjusts Price Target on Exelixis to $36 From $37, Maintains B..
MT
More recommendations
Press releases
11/22Exelixis Announces Detailed Results from Phase 3 COSMIC-312 Pivotal Trial of Cabozantin..
AQ
11/20Exelixis Announces Detailed Results from Phase 3 COSMIC-312 Pivotal Trial of Cabozantin..
BU
11/09Exelixis Announces Enrollment Completion in Phase 3 CONTACT-01 Pivotal Trial of Cabozan..
BU
11/03Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in November ..
BU
11/02EXELIXIS : Q3 Earnings Snapshot
AQ
More press releases
Upcoming event on EXELIXIS, INC.